FDA approves Celgene's Thalomid for myeloma

Celgene has received an approvable letter from the FDA to expand the use of Thalomid for multiple myeloma. The letter typically indicates that a drug developer will need to submit additional information before final approval is given. Thalomid is approved for leprosy but is often used off-label for cancer.

- read this AP report for more

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.